bioRxivCancer Biology
XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells
T. Zou, M. Zhou, A. Gupta, P. Zhuang, A. R. Fishbein, H. Y. Wei, Z. Zhang, A. D. Cherniack, M. Meyerson
Abstract
Emerging data suggest that induction of viral mimicry responses through activation of double-stranded RNA (dsRNA) sensors in cancer cells is a promising therapeutic strategy. One approach to induce viral mimicry is to target molecular regulators of dsRNA sensing pathways. Here, we show that the exoribonuclease XRN1 is a negative regulator of the dsRNA sensor protein kinase R (PKR) in cancer cells with high interferon-stimulated gene (ISG) expression. XRN1 deletion causes PKR activation and consequent cancer cell lethality. Disruption of interferon signaling with the JAK1/2 inhibitor ruxolitinib can decrease cellular PKR levels and rescue sensitivity to XRN1 deletion. Conversely, interferon-{beta} stimulation can increase PKR levels and induce sensitivity to XRN1 inactivation. Lastly, XRN1 deletion causes accumulation of endogenous complementary sense/anti-sense RNAs, which may represent candidate PKR ligands. Our data demonstrate how XRN1 regulates PKR and nominate XRN1 as a potential therapeutic target in cancer cells with an activated interferon cell state.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inhibiting DDX3X triggers tumor-intrinsic type I interferon response and enhances anti-tumor immunity
- The roles of RNA editing in cancer immunity through interacting with interferon
Sijia Wu, Xinyu Qin, … Liyu Huang·bioRxiv·Aug 6, 2023
- Induction of viral mimicry upon loss of DHX9 and ADAR1 in breast cancer cells
Kyle A. Cottrell, Sua Ryu, … Jason D. Weber·Cancer Research CommunicationsPeer-reviewed·Mar 26, 2024
- Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer
A. Hosseini, H. T. Lindholm, … D. D. De Carvalho·bioRxiv·Mar 30, 2023
- PACT suppresses PKR activation through dsRNA binding and dimerization, and is a therapeutic target for triple-negative breast cancer
Addison A. Young, Isabelle G. Juhler, … Kyle A. Cottrell·RNAPeer-reviewed·Aug 13, 2025
- Cooperative Role of PACT and ADAR1 in Preventing Aberrant PKR Activation by Self-Derived Double-Stranded RNA
Lavanya Manjunath, Gisselle Santiago, … Rémi Buisson·Nature CommunicationsPeer-reviewed·Apr 5, 2025